Tech Company Financing Transactions
Augustine Therapeutics Funding Round
On 3/24/2025, Augustine Therapeutics raised $84 million in Series A funding from Jeito Capital, Novo Holdings and AdBio Partners.
Transaction Overview
Company Name
Announced On
3/24/2025
Transaction Type
Venture Equity
Amount
$84,000,000
Round
Series A
Investors
Jeito Capital (Lead Investor)
Novo Holdings (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead candidate, AGT-100216, through a Phase I/II proof-of-concept clinical trial in CMT.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Gaston Geenslaan 1
Leuven, 3001
Belgium
Leuven, 3001
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Augustine Therapeutics was founded in 2019 as a spin-off of VIB and KU Leuven. Based on the groundbreaking neurological research of Prof. Ludo Van Den Bosch, this early drug discovery company is building a portfolio of first-in-class therapies for rare neuromuscular neurodegenerative diseases. Augustine Therapeutics' approach is based on new insights into the neuroprotective potential of small-molecule HDAC6 inhibitors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Gerhard Koenig
Chief Executive Officer
Sylvain Celanire
Chief Financial Officer
Christophe Van Vaeck
Vice President
Frederik Rombouts
Browse more venture capital transactions:
Prev: 3/24/2025: Enza venture capital transaction
Next: 3/24/2025: Faraday Future venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs